Depletion of Mettl3 and Mettl14 significantly upregulated PD-L1, and Mettl3 or Mettl14 deficient enhanced the response to anti-PD-1 treatment in pMMR-MSI-L CRC and melanoma. This evidence concerns the gene PDCD1 and melanoma.